Targeting Myeloid-Derived Suppressor Cells in Cancer.

[1]  M. Shurin,et al.  Myeloid regulatory cells in tumor spreading and metastasis. , 2015, Immunobiology.

[2]  Jing-wei Jiang,et al.  Phenotypes, accumulation, and functions of myeloid-derived suppressor cells and associated treatment strategies in cancer patients. , 2014, Human immunology.

[3]  S. Sengupta,et al.  Interleukin-13 Receptor Alpha 2-Targeted Glioblastoma Immunotherapy , 2014, BioMed research international.

[4]  T. Voloshin,et al.  Anti-Bv8 Antibody and Metronomic Gemcitabine Improve Pancreatic Adenocarcinoma Treatment Outcome Following Weekly Gemcitabine Therapy12 , 2014, Neoplasia.

[5]  B. Han,et al.  Origin and pharmacological modulation of tumor‐associated regulatory dendritic cells , 2014, International journal of cancer.

[6]  C. Muller,et al.  A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study. , 2014, Gynecologic oncology.

[7]  R. DiPaola,et al.  Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501) , 2014, Cancer Chemotherapy and Pharmacology.

[8]  D. Conrad,et al.  Mast cells and mast cell-derived IL-13 play an important role in MDSC activation, migration, and accumulation. (TUM4P.925) , 2014, Journal of Immunology.

[9]  L. E. Fernández,et al.  Very small size proteoliposomes abrogate cross-presentation of tumor antigens by myeloid-derived suppressor cells and induce their differentiation to dendritic cells , 2014, Journal of Immunotherapy for Cancer.

[10]  Sabrin H Albeituni,et al.  Hampering Immune Suppressors: Therapeutic Targeting of Myeloid-Derived Suppressor Cells in Cancer , 2013, Cancer journal.

[11]  P. Dutta,et al.  Role of the JAK‐STAT Signalling Pathway in Cancer , 2013 .

[12]  D. Schadendorf,et al.  Vemurafenib reverses immunosuppression by myeloid derived suppressor cells , 2013, International journal of cancer.

[13]  J. Khan,et al.  Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. , 2013, Blood.

[14]  J. Markowitz,et al.  Myeloid derived suppressor cells – a new therapeutic target in the treatment of cancer , 2013, Journal of Immunotherapy for Cancer.

[15]  Ge Ma,et al.  Polarization and reprogramming of myeloid-derived suppressor cells. , 2013, Journal of molecular cell biology.

[16]  K. Pienta,et al.  Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer , 2013, Investigational New Drugs.

[17]  Yue Zhang,et al.  β‐Glucan enhances antitumor immune responses by regulating differentiation and function of monocytic myeloid‐derived suppressor cells , 2013, European journal of immunology.

[18]  Stephen Mok,et al.  CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. , 2013, Cancer research.

[19]  Ke-Xing Fan,et al.  Cimetidine suppresses lung tumor growth in mice through proapoptosis of myeloid-derived suppressor cells. , 2013, Molecular immunology.

[20]  R. Vessella,et al.  Inhibition of CCL2 Signaling in Combination with Docetaxel Treatment Has Profound Inhibitory Effects on Prostate Cancer Growth in Bone , 2013, International journal of molecular sciences.

[21]  J. Gustafsson,et al.  The oxysterol–CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils , 2013, The Journal of experimental medicine.

[22]  Yanping Zhang,et al.  Abstract 4995: Tumor-dervied gammadelta regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence. , 2013 .

[23]  J. Wolchok,et al.  Hepatotoxicity with combination of vemurafenib and ipilimumab. , 2013, The New England journal of medicine.

[24]  J. Mier,et al.  Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells , 2013, Molecular Cancer.

[25]  Yanping Zhang,et al.  Tumor-Derived γδ Regulatory T Cells Suppress Innate and Adaptive Immunity through the Induction of Immunosenescence , 2013, The Journal of Immunology.

[26]  Bin Zhang,et al.  Circulating and Tumor-Infiltrating Myeloid-Derived Suppressor Cells in Patients with Colorectal Carcinoma , 2013, PloS one.

[27]  N. Harashima,et al.  Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo , 2013, Cancer Immunology, Immunotherapy.

[28]  M. Hollingsworth,et al.  Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer , 2013, Cancer Immunology, Immunotherapy.

[29]  Wilfrid Boireau,et al.  Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth , 2012, Nature Medicine.

[30]  A. Sarnaik,et al.  Blockade of Myeloid-Derived Suppressor Cells after Induction of Lymphopenia Improves Adoptive T Cell Therapy in a Murine Model of Melanoma , 2012, The Journal of Immunology.

[31]  A. Sevko,et al.  Myeloid-Derived Suppressor Cells Interact with Tumors in Terms of Myelopoiesis, Tumorigenesis and Immunosuppression: Thick as Thieves , 2012, Journal of Cancer.

[32]  P. Lu,et al.  Cucurbitacin B regulates immature myeloid cell differentiation and enhances antitumor immunity in patients with lung cancer. , 2012, Cancer biotherapy & radiopharmaceuticals.

[33]  G. Nieto,et al.  Very small size proteoliposomes (VSSP) and Montanide combination enhance the humoral immuno response in a GnRH based vaccine directed to prostate cancer. , 2012, Vaccine.

[34]  P. Kalinski,et al.  Generation of myeloid-derived suppressor cells using prostaglandin E2 , 2012, Transplantation research.

[35]  A. Sevko,et al.  Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner , 2012, Journal of immunotoxicology.

[36]  S. Terada,et al.  Anti‐IL‐6 receptor mAb eliminates myeloid‐derived suppressor cells and inhibits tumor growth by enhancing T‐cell responses , 2012, European journal of immunology.

[37]  Jennifer L. Taylor,et al.  Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells. , 2012, Cancer research.

[38]  P. Sinha,et al.  Regulating the suppressors: apoptosis and inflammation govern the survival of tumor-induced myeloid-derived suppressor cells (MDSC) , 2012, Cancer Immunology, Immunotherapy.

[39]  M. Stewart.  Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug , 2012, British Journal of Ophthalmology.

[40]  D. Gabrilovich,et al.  Coordinated regulation of myeloid cells by tumours , 2012, Nature Reviews Immunology.

[41]  J. Bromberg,et al.  Targeting the interleukin-6/Jak/stat pathway in human malignancies. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  P. Dahm,et al.  Circulating and tumor‐infiltrating myeloid cell subsets in patients with bladder cancer , 2012, International journal of cancer.

[43]  Y. Morera,et al.  CIGB-247: a VEGF-based therapeutic vaccine that reduces experimental and spontaneous lung metastasis of C57Bl/6 and BALB/c mouse tumors. , 2012, Vaccine.

[44]  L. Koniaris,et al.  Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II–IIIc breast cancer , 2012, Breast Cancer Research and Treatment.

[45]  S. Rosenberg,et al.  Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice , 2012, Clinical Cancer Research.

[46]  C. Hsieh,et al.  Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth , 2012, Cancer Immunology, Immunotherapy.

[47]  S. Biswas,et al.  Characterization of the nature of granulocytic myeloid‐derived suppressor cells in tumor‐bearing mice , 2012, Journal of leukocyte biology.

[48]  F. Marincola,et al.  IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. , 2011, The Journal of clinical investigation.

[49]  Angélica Figueroa,et al.  New Insights into Molecular Mechanisms of Sunitinib-Associated Side Effects , 2011, Molecular Cancer Therapeutics.

[50]  P. Robbins,et al.  The Roles of Tumor-Derived Exosomes in Cancer Pathogenesis , 2011, Clinical & developmental immunology.

[51]  J. Berzofsky,et al.  A Novel Combination Immunotherapy for Cancer by IL-13Rα2–Targeted DNA Vaccine and Immunotoxin in Murine Tumor Models , 2011, The Journal of Immunology.

[52]  A. Epstein,et al.  Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors. , 2011, Immunotherapy.

[53]  Simon C Watkins,et al.  Sunitinib facilitates the activation and recruitment of therapeutic anti‐tumor immunity in concert with specific vaccination , 2011, International journal of cancer.

[54]  Timothy C Wang,et al.  Curcumin Induces the Differentiation of Myeloid-Derived Suppressor Cells and Inhibits Their Interaction with Cancer Cells and Related Tumor Growth , 2011, Cancer Prevention Research.

[55]  D. Schadendorf,et al.  Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model , 2011, Proceedings of the National Academy of Sciences.

[56]  M. Sporn,et al.  Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. , 2011, The Journal of clinical investigation.

[57]  L. Lazzarato,et al.  Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells , 2011, The Journal of experimental medicine.

[58]  G. Srikrishna.  S100A8 and S100A9: New Insights into Their Roles in Malignancy , 2011, Journal of Innate Immunity.

[59]  G. Lesinski,et al.  Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. , 2011, Cancer research.

[60]  B. Rini,et al.  MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. , 2011, International immunopharmacology.

[61]  M. Roncalli,et al.  Modulation of human T‐cell functions by reactive nitrogen species , 2011, European journal of immunology.

[62]  W. Fellows-Mayle,et al.  COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. , 2011, Cancer research.

[63]  P. López-Saura,et al.  Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial , 2011, ISRN obstetrics and gynecology.

[64]  Yanping Zhang,et al.  The role of interleukin‐12 on modulating myeloid‐derived suppressor cells, increasing overall survival and reducing metastasis , 2011, Immunology.

[65]  R. Benya,et al.  Phase IIa Clinical Trial of Curcumin for the Prevention of Colorectal Neoplasia , 2011, Cancer Prevention Research.

[66]  Alessia Ricupito,et al.  Modulators of Arginine Metabolism Do Not Impact on Peripheral T-Cell Tolerance and Disease Progression in a Model of Spontaneous Prostate Cancer , 2011, Clinical Cancer Research.

[67]  S. Endres,et al.  CpG Blocks Immunosuppression by Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice , 2011, Clinical Cancer Research.

[68]  V. Bronte,et al.  Inhibition of Tumor-Induced Myeloid-Derived Suppressor Cell Function by a Nanoparticulated Adjuvant , 2011, The Journal of Immunology.

[69]  D. Munn,et al.  Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. , 2010, Blood.

[70]  G. Bhagat,et al.  Histamine deficiency promotes inflammation-associated carcinogenesis through reduced myeloid maturation and accumulation of CD11b+Ly6G+ immature myeloid cells , 2010, Nature Medicine.

[71]  Thijs J. Hagenbeek,et al.  Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes , 2010, Proceedings of the National Academy of Sciences.

[72]  Je-in Youn,et al.  The biology of myeloid‐derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity , 2010, European journal of immunology.

[73]  S. Singhal,et al.  Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[74]  J. Vieweg,et al.  Pivotal Advance: Tumor‐mediated induction of myeloid‐derived suppressor cells and M2‐polarized macrophages by altering intracellular PGE2 catabolism in myeloid cells , 2010, Journal of leukocyte biology.

[75]  Li Lin,et al.  A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells , 2010, Molecular Cancer.

[76]  D. Gilvary,et al.  A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers , 2010, Clinical Cancer Research.

[77]  M. B. Gillespie,et al.  Use of alpha,25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma. , 2010, Human immunology.

[78]  D. Mougiakakos,et al.  Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. , 2010, Cancer research.

[79]  B. Rini,et al.  Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. , 2010, Cancer research.

[80]  J. Vincent,et al.  5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. , 2010, Cancer research.

[81]  M. Sporn,et al.  Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer , 2010, Clinical Cancer Research.

[82]  C. Elmets,et al.  IL-17 Promotes Tumor Development through the Induction of Tumor Promoting Microenvironments at Tumor Sites and Myeloid-Derived Suppressor Cells , 2010, The Journal of Immunology.

[83]  A. Lusis,et al.  Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. , 2010, Blood.

[84]  B. Chauffert,et al.  Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. , 2010, The Journal of clinical investigation.

[85]  S. Ugel,et al.  Therapeutic targeting of myeloid-derived suppressor cells. , 2009, Current opinion in pharmacology.

[86]  P. Sinha,et al.  Myeloid-Derived Suppressor Cells Down-Regulate L-Selectin Expression on CD4+ and CD8+ T Cells1 , 2009, The Journal of Immunology.

[87]  H. Bear,et al.  Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. , 2009, International immunopharmacology.

[88]  G. C. Chan,et al.  The effects of β-glucan on human immune and cancer cells , 2009, Journal of Hematology & Oncology.

[89]  A. Poliakov,et al.  Induction of myeloid‐derived suppressor cells by tumor exosomes , 2009, International journal of cancer.

[90]  R. Greil,et al.  Endocrine therapy plus zoledronic acid in premenopausal breast cancer. , 2009, The New England journal of medicine.

[91]  R. Figlin,et al.  Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. , 2009, Cancer research.

[92]  C. Divino,et al.  The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. , 2009, Cancer research.

[93]  B. Rini,et al.  Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients , 2009, Clinical Cancer Research.

[94]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[95]  M. Atkins,et al.  Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. , 2009, Cancer research.

[96]  M. B. Gillespie,et al.  1α,25-Dihydroxyvitamin D3 to skew intratumoral levels of immune inhibitory CD34+ progenitor cells into dendritic cells , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[97]  M. Freschi,et al.  Modulators of arginine metabolism support cancer immunosurveillance , 2009, BMC Immunology.

[98]  P. Dahm,et al.  Reversal of Myeloid Cell–Mediated Immunosuppression in Patients with Metastatic Renal Cell Carcinoma , 2008, Clinical Cancer Research.

[99]  Michelle Collazo,et al.  Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice1 , 2008, The Journal of Immunology.

[100]  D. Foell,et al.  Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells1 , 2008, The Journal of Immunology.

[101]  G. Giaccone,et al.  Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival , 2008, Clinical Cancer Research.

[102]  D. Foell,et al.  RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis , 2008, Carcinogenesis.

[103]  Razelle Kurzrock,et al.  Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer , 2008, Clinical Cancer Research.

[104]  M. Andreeff,et al.  Phase I trial with a novel oral NF-{kappa}B/STAT3 inhibitor RTA 402 in patients with solid tumors and lymphoid malignancies , 2008 .

[105]  C. Chuang,et al.  Pretreatment with Cisplatin Enhances E7-Specific CD8+ T-Cell–Mediated Antitumor Immunity Induced by DNA Vaccination , 2008, Clinical Cancer Research.

[106]  A. Ho,et al.  Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma. , 2008, Future oncology.

[107]  G. Weiner,et al.  CpG oligodeoxynucleotides as immunotherapy in cancer. , 2008, Update on cancer therapeutics.

[108]  D. Kranz,et al.  Equilibrium between host and cancer caused by effector T cells killing tumor stroma. , 2008, Cancer research.

[109]  P. De Baetselier,et al.  Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. , 2008, Blood.

[110]  F. Peale,et al.  Bv8 regulates myeloid-cell-dependent tumour angiogenesis , 2007, Nature.

[111]  Z. Werb,et al.  Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. , 2007, Cancer research.

[112]  M. Sporn,et al.  Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils. , 2007, Antioxidants & redox signaling.

[113]  K. Matthay,et al.  A phase 2 trial of all‐trans‐retinoic acid in combination with interferon‐α2a in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch, NCI and Children's Oncology Group Study , 2007 .

[114]  J. Sosman,et al.  Vascular Endothelial Growth Factor-Trap Overcomes Defects in Dendritic Cell Differentiation but Does Not Improve Antigen-Specific Immune Responses , 2007, Clinical Cancer Research.

[115]  S. Albelda,et al.  Cross-Talk between Myeloid-Derived Suppressor Cells and Macrophages Subverts Tumor Immunity toward a Type 2 Response1 , 2007, The Journal of Immunology.

[116]  R. C. van der Veen,et al.  Mycobacteria‐induced Gr‐1+ subsets from distinct myeloid lineages have opposite effects on T cell expansion , 2007, Journal of leukocyte biology.

[117]  D. Quiceno,et al.  L-arginine availability regulates T-lymphocyte cell-cycle progression. , 2007, Blood.

[118]  Steffen Jung,et al.  Monocytes give rise to mucosal, but not splenic, conventional dendritic cells , 2007, The Journal of experimental medicine.

[119]  P. Rodriguez,et al.  Arginase, Prostaglandins, and Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[120]  J. Califano,et al.  Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function , 2006, The Journal of experimental medicine.

[121]  A. Ullrich,et al.  Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant , 2006, International journal of cancer.

[122]  Ingo Fricke,et al.  All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. , 2006, Cancer research.

[123]  J. Pollard,et al.  Conditional deletion of the colony stimulating factor‐1 receptor (c‐fms proto‐oncogene) in mice , 2006, Genesis.

[124]  L. E. Fernández,et al.  Very small size proteoliposomes derived from Neisseria meningitidis: An effective adjuvant for generation of CTL responses to peptide and protein antigens. , 2006, Vaccine.

[125]  Shufeng Zhou,et al.  Monitoring of immune responses to a herbal immuno-modulator in patients with advanced colorectal cancer. , 2006, International immunopharmacology.

[126]  C. Divino,et al.  Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. , 2006, Cancer research.

[127]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[128]  Xin-shu Dong,et al.  Effect of a nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester on invasion of human colorectal cancer cell line SL-174T. , 2005, World journal of gastroenterology.

[129]  S. Dubinett,et al.  Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma , 2005, The Journal of experimental medicine.

[130]  M. Young,et al.  Combination Docetaxel plus Vitamin D3 as an Immune Therapy in Animals Bearing Squamous Cell Carcinomas , 2005, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[131]  L. Kaiser,et al.  Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity , 2005, Clinical Cancer Research.

[132]  Shufeng Zhou,et al.  Effects of water-soluble Ganoderma lucidum polysaccharides on the immune functions of patients with advanced lung cancer. , 2005, Journal of medicinal food.

[133]  P. Musiani,et al.  Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[134]  K. Hoag,et al.  Physiological concentrations of retinoic acid favor myeloid dendritic cell development over granulocyte development in cultures of bone marrow cells from mice. , 2004, The Journal of nutrition.

[135]  P. Payette,et al.  Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll‐like receptor 9 dependent T helper type 2 biased immune stimulation , 2004, Immunology.

[136]  V. Bronte,et al.  High-Dose Granulocyte-Macrophage Colony-Stimulating Factor-Producing Vaccines Impair the Immune Response through the Recruitment of Myeloid Suppressor Cells , 2004, Cancer Research.

[137]  L. E. Fernández,et al.  Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation. , 2004, Vaccine.

[138]  Joseph I. Clark,et al.  Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3 , 2004, Cancer Immunology, Immunotherapy.

[139]  J. Bastien,et al.  Nuclear retinoid receptors and the transcription of retinoid-target genes. , 2004, Gene.

[140]  D. Gabrilovich,et al.  Antigen-Specific Inhibition of CD8+ T Cell Response by Immature Myeloid Cells in Cancer Is Mediated by Reactive Oxygen Species1 , 2004, The Journal of Immunology.

[141]  Bin Yu,et al.  All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. , 2003, Cancer research.

[142]  D. Yee,et al.  Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[143]  N. Tsavaris,et al.  Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes , 2002, British Journal of Cancer.

[144]  S. Rafii,et al.  Recruitment of Stem and Progenitor Cells from the Bone Marrow Niche Requires MMP-9 Mediated Release of Kit-Ligand , 2002, Cell.

[145]  D. Gabrilovich,et al.  Immature myeloid cells and cancer-associated immune suppression , 2002, Cancer Immunology, Immunotherapy.

[146]  G. Filomeni,et al.  Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[147]  S. Jee,et al.  Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. , 2001, Anticancer research.

[148]  O. Finn,et al.  Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. , 2001, Cancer research.

[149]  Nicholas R. English,et al.  Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.

[150]  A. Morelli,et al.  IL-1β Converting Enzyme Is a Target for Nitric Oxide-Releasing Aspirin: New Insights in the Antiinflammatory Mechanism of Nitric Oxide-Releasing Nonsteroidal Antiinflammatory Drugs , 2000, The Journal of Immunology.

[151]  I. Wang,et al.  Vitamin A deficiency in mice causes a systemic expansion of myeloid cells , 2000 .

[152]  I. Weissman,et al.  A clonogenic common myeloid progenitor that gives rise to all myeloid lineages , 2000, Nature.

[153]  M. Young,et al.  Skewed differentiation of bone marrow CD34+ cells of tumor bearers from dendritic toward monocytic cells, and the redirection of differentiation toward dendritic cells by 1alpha,25-dihydroxyvitamin D3. , 1999, International journal of immunopharmacology.

[154]  L. E. Fernández,et al.  Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). , 1999, Vaccine.

[155]  H. Nemoto,et al.  A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group. , 1999, Hepato-gastroenterology.

[156]  M. Zeng,et al.  Fas-induced caspase denitrosylation. , 1999, Science.

[157]  D. Wallwiener,et al.  Reduction in new metastases in breast cancer with adjuvant clodronate treatment. , 1998, The New England journal of medicine.

[158]  S. Rosenberg.  Cancer vaccines based on the identification of genes encoding cancer regression antigens. , 1997, Immunology today.

[159]  G. Rodan,et al.  Bisphosphonates: mechanisms of action , 1998, Endocrine reviews.

[160]  H. Schreiber,et al.  Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[161]  H. Claman,et al.  Murine natural suppressor cells in the newborn, in bone marrow, and after cyclophosphamide. Genetic variations and dependence on IFN-gamma. , 1989, Journal of immunology.

[162]  T. Graeber,et al.  Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. , 2014, Cancer research.

[163]  M. Shurin,et al.  Clinical evaluation of systemic and local immune responses in cancer: time for integration , 2013, Cancer Immunology, Immunotherapy.

[164]  D. Gabrilovich,et al.  Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. , 2011, Trends in immunology.

[165]  P. Sinha,et al.  Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. , 2010, Cancer research.

[166]  G. Lesinski,et al.  The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity , 2010, Molecular Cancer.

[167]  M. Nishimura,et al.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy , 2008, Cancer Immunology, Immunotherapy.

[168]  C. Divino,et al.  Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. , 2008, Blood.

[169]  P. Rodriguez,et al.  Mechanisms of tumor evasion from the immune response. , 2003, Cancer chemotherapy and biological response modifiers.

[170]  R. Russell,et al.  Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. , 2002 .

[171]  T. Habermann,et al.  Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. , 2002, Blood.

[172]  N. Mitsuhashi,et al.  Effect of Krestin as adjuvant treatment following radical radiotherapy in non-small cell lung cancer patients. , 1997, Cancer detection and prevention.

[173]  A. S. Pak,et al.  Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[174]  M. Yamasaki,et al.  Improvement of long-term prognosis in patients with ovarian cancers by adjuvant sizofiran immunotherapy: a prospective randomized controlled study , 1993, Biotherapy.